It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 13% over the past three months. However, stock prices are usually driven by a company ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings conference call with institutional ...

Bengalureans! We know how much you love exploring new restaurants, pubs and cafes in the hood. After all, eating out counts as a hobby, doesn’t it? We are as excited as you are. Perhaps, even more, as ...

Merck's Keytruda could face competition from a newer medicine. The company's crown jewel will also lose patent exclusivity in a few years. Merck should have the means to get around these headwinds ...

Merck, a global pharmaceutical company, uses synthetic data and AWS services to reduce false reject rates in their drug inspection process. The company has reduced its false reject rate by 50% by ...

The Karnataka Government Friday unveiled the draft of India’s first-ever Global Capability Centre (GCC) policy. The policy outlines a vision to establish 500 new GCCs by 2029, contributing ...

joined by Merck Global Health Innovation Fund and Kae Capital, says a company statement. The investment will expedite expansion into the US market and other geographies, increase investment into ...

Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...

The agreement grants Merck the option to license Evaxion’s preclinical vaccine candidates EVX-B2 and EVX-B3. Evaxion also granted Merck an option to license preclinical vaccine candidates EVX-B2 ...

Bangalore is a major educational hub in India, with a wide range of schools to choose from. Whether you are looking for a private school, a government school, or an international school, Bangalore ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...